Emerging evidence suggests that retatrutide, a novel dual-action peptide activator targeting both GLP-1 and GIP receptors, could represent a significant advance in obesity treatment therapies. Unlike https://reta869053.pointblog.net/retatrutide-a-novel-peptide-for-weight-management-98173960